Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 202 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Arcadia, California
Conditions
Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
Interventions
Daratumumab SC, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York + 1 more
Conditions
Brain Tumors
Interventions
temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Months to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
16
States / cities
Phoenix, Arizona • Atlanta, Georgia • Lihue, Hawaii + 13 more
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Conditions
Brain Tumor, Medulloblastoma, Brain Metastases
Interventions
WP1066
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
enzastaurin hydrochloride
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, carmustine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
51
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 40 more
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Extra-adrenal Paraganglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, tamoxifen citrate, topotecan hydrochloride, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Duarte, California
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Conditions
Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer, Leukemia
Interventions
Enhanced Mindfulness Intervention, Psychoeducation
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma
Interventions
Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
Biological · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
11
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Conditions
Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
Interventions
Pazopanib (GW786034)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Cancer
Interventions
Genetically Informed Therapy
Genetic
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
valproic acid
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
15
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
Conditions
Brain and Central Nervous System Tumors
Interventions
CC-8490
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma
Interventions
lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Lonafarnib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, irinotecan hydrochloride
Biological · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Intracranial Meningioma
Interventions
Everolimus, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Orlando, Florida • Louisville, Kentucky • Omaha, Nebraska + 4 more
Conditions
Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers, Gynecologic Cancers, Head and Neck Cancers, Melanoma, Thoracic Cancers
Interventions
IGF-Methotrexate conjugate
Drug
Lead sponsor
IGF Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, paclitaxel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
Interventions
25 mCi 177Lu- DTPA-omburtamab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 22 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more